about
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administrationSimple method for the assay of linezolid in Brain Heart Infusion broth by high-performance liquid chromatography.High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma.A palliative cancer care flexible education program for Australian community pharmacistsPharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Hepatic disposition of electrophilic acyl glucuronide conjugates.The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis.Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatmentColistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.Disposition of betamethasone in parturient women after intramuscular administrationColistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii.Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach.Imaging the distribution of polymyxins in the kidneyPopulation pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsNovel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiMajor pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells.Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosaEffect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopyDrug release from nanomedicines: Selection of appropriate encapsulation and release methodology.Stereoselective drug disposition: potential for misinterpretation of drug disposition data.Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations.Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37.Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiSynergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Optimizing use of colistin and polymyxin B in the critically ill.Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.Transcriptomic Analysis of the Activity of a Novel Polymyxin against Staphylococcus aureus.Management of meningitis due to antibiotic-resistant Acinetobacter species.Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment.Quantitation of Polymyxin-Lipopolysaccharide Interactions Using an Image-Based Fluorescent Probe.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
P50
Q24682618-7094E4BD-7130-4EC8-A590-1A31134509C3Q33197926-5ABCA5E4-E322-4C9B-A85B-E0DA1D8BE1EBQ33227356-6860FCA9-D9BF-4401-9FF4-A0FEF66C7DE8Q33796828-E29BE13E-AAFA-4A92-961E-D8F4ABF35C65Q33976935-7292E309-C9A7-4204-9E4B-BEA7760B6507Q34060378-92F36228-9141-40F5-B2FF-6D116F974C3CQ34108660-4E2ED701-9676-4CEF-A595-16564F96D1DFQ34314728-FB963EFB-A78D-4556-8034-A5D4ADFA0987Q34345693-42246B3B-165D-48E6-BDFD-02C2E01CA0A6Q34405889-CD7808A4-B345-4E6D-872B-52D59E294D56Q34560321-4D07E793-5992-43DF-87FC-6E47347CE38DQ34621990-9D7138E7-478A-418D-BFA5-56D2BA9C43FFQ34680516-9D00CD0A-94C2-4ABF-ABD9-3B82134C5EB7Q34922570-86C39023-ED2D-4B06-8592-ABB4005F83EEQ35005140-66CFF7AE-B535-4F91-9F37-19C3BC8290D4Q35054109-21C4ACF5-641D-45FE-BCB7-560B72D6767EQ35056878-99586438-5393-4281-9E45-942B1A69A000Q35065863-22157000-4528-4ED0-803C-EF6B7C402C26Q35168931-134D3037-90E2-4123-9307-1F56B200E98AQ35168993-1B3BC585-C436-4567-B709-78D494DEFEF1Q35432770-A02801F7-35D1-4600-AB2F-C8AE56720789Q35666622-3A68F797-0AD1-4906-A4D8-C8C2A9A1EE7DQ36207747-80C57049-074C-44CE-86BB-CB1B75296943Q36350400-5DA48C0B-EC3E-4206-A412-282222BD60F6Q36442244-E561DC54-DD83-49ED-8532-4847CF5EE0D0Q36443346-AE0F6771-75D8-4A71-9394-1637429D070EQ36543850-80B0D452-1DF2-42C6-9F0A-72ECFDCC8C73Q36646684-1087DAF6-D46B-4F31-8286-AFAF405B418AQ36729133-7B392005-FAD4-4F9C-9800-2BC7A6DC69F3Q36915742-D54EB05E-EA51-40C5-9B20-7EB40AE404BAQ37023206-AA4B43A4-C264-4153-8C92-4ECE23BF7B54Q37036489-AE123909-B4B7-4380-A70B-B9E738EFE47AQ37038581-72083CE5-0C7C-44F1-8C75-A7A44E0DB4F5Q37124182-9D67CA43-A7DF-4C97-8DEC-6D0B91FFB2AFQ37132130-1D2131D8-271F-4978-8CB4-523A28F401C6Q37382976-EAAD898E-4DEF-4F85-8586-AF901B08F1D8Q37450764-E5344DA2-6948-44D0-BD2B-03151ACEC368Q37491825-964B720A-3246-4E6B-A2FA-CD89BE178ADBQ37538623-F828586C-3F5D-4002-B764-B9C9C45D29D2Q37538748-B815A4C8-37B9-4BA6-9950-56D963106008
P50
description
researcher, ORCID id # 0000-0003-1492-8590
@en
wetenschapper
@nl
name
Roger L Nation
@ast
Roger L Nation
@en
Roger L Nation
@es
Roger L Nation
@nl
type
label
Roger L Nation
@ast
Roger L Nation
@en
Roger L Nation
@es
Roger L Nation
@nl
prefLabel
Roger L Nation
@ast
Roger L Nation
@en
Roger L Nation
@es
Roger L Nation
@nl
P244
P106
P1153
7005596529
P21
P214
66146095347700372533
P244
no2016036356
P31
P496
0000-0003-1492-8590
P735
P7859
lccn-no2016036356